MX2023002064A - Produccion estereoselectiva de fosforamidatos de purina seleccionados. - Google Patents

Produccion estereoselectiva de fosforamidatos de purina seleccionados.

Info

Publication number
MX2023002064A
MX2023002064A MX2023002064A MX2023002064A MX2023002064A MX 2023002064 A MX2023002064 A MX 2023002064A MX 2023002064 A MX2023002064 A MX 2023002064A MX 2023002064 A MX2023002064 A MX 2023002064A MX 2023002064 A MX2023002064 A MX 2023002064A
Authority
MX
Mexico
Prior art keywords
manufacture
phosphoramidates
stereoselective
selected purine
purine
Prior art date
Application number
MX2023002064A
Other languages
English (en)
Inventor
Adel Moussa
Narayan Chaudhuri
Original Assignee
Atea Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atea Pharmaceuticals Inc filed Critical Atea Pharmaceuticals Inc
Publication of MX2023002064A publication Critical patent/MX2023002064A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/02—Phosphorylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Luminescent Compositions (AREA)

Abstract

La presente invención provee procedimientos de producción estereoselectivos para el compuesto 1 de nucleótido de fosforamidato, o una sal farmacéuticamente aceptable del mismo.
MX2023002064A 2020-08-19 2021-08-19 Produccion estereoselectiva de fosforamidatos de purina seleccionados. MX2023002064A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063067726P 2020-08-19 2020-08-19
US202063074302P 2020-09-03 2020-09-03
US202063094759P 2020-10-21 2020-10-21
US202063129306P 2020-12-22 2020-12-22
PCT/US2021/046778 WO2022040473A1 (en) 2020-08-19 2021-08-19 Stereoselective manufacture of selected purine phosphoramidates

Publications (1)

Publication Number Publication Date
MX2023002064A true MX2023002064A (es) 2023-03-16

Family

ID=80323295

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002064A MX2023002064A (es) 2020-08-19 2021-08-19 Produccion estereoselectiva de fosforamidatos de purina seleccionados.

Country Status (10)

Country Link
US (1) US20230331751A1 (es)
EP (1) EP4200309A1 (es)
JP (1) JP2023538594A (es)
KR (1) KR20230053640A (es)
CN (1) CN115884977A (es)
AU (1) AU2021327241A1 (es)
CA (1) CA3173661A1 (es)
MX (1) MX2023002064A (es)
TW (1) TW202214260A (es)
WO (1) WO2022040473A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102335193B1 (ko) 2017-02-01 2021-12-03 아테아 파마슈티컬즈, 인크. C형 간염 바이러스를 치료하기 위한 뉴클레오티드 헤미-술페이트 염
WO2023173196A1 (en) 2022-03-18 2023-09-21 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150027155A (ko) * 2012-07-03 2015-03-11 브리스톨-마이어스 스큅 컴퍼니 바이러스 감염의 치료를 위한 뉴클레오시드 화합물의 부분입체이성질체적으로 풍부한 포스포르아미데이트 유도체의 제조 방법
IL295418B2 (en) * 2015-03-06 2023-10-01 Atea Pharmaceuticals Inc Cell-D-2'-deoxy-2'-alpha-fluoro-2'-cell-C-modified-2-different-N6-purine modified nucleotides for the treatment of hepatitis C virus

Also Published As

Publication number Publication date
WO2022040473A1 (en) 2022-02-24
AU2021327241A1 (en) 2023-04-20
KR20230053640A (ko) 2023-04-21
JP2023538594A (ja) 2023-09-08
CN115884977A (zh) 2023-03-31
US20230331751A1 (en) 2023-10-19
TW202214260A (zh) 2022-04-16
EP4200309A1 (en) 2023-06-28
CA3173661A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
MX2023002064A (es) Produccion estereoselectiva de fosforamidatos de purina seleccionados.
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
DE602005014936D1 (en) Phosphoramidatderivate
WO2016096174A8 (en) Cyclic dinucleotides for cytokine induction
MX2019014914A (es) Sintesis de 3'-desoxiadenosina-5'-0-[fenil(benciloxi-l-alaninil)]f osfato (nuc-7738).
BRPI0512690A (pt) análogos de fosfonato de compostos inibidores de hiv
SG11201903875QA (en) Selective inhibitor of exon 20 insertion mutant egfr
BR112021002090A8 (pt) Derivado azabicíclico opticamente ativo
MX2021011606A (es) Compuestos dirigidos a prmt5.
WO2007067364A3 (en) Methods of treating cancer and other conditions or disease states using l-cytosine nucleoside analogs
SG10201907898SA (en) Gemcitabine prodrugs
EA200800002A1 (ru) Способы лечения рака и других заболеваний или патологических состояний с применением клевудина (lfmau) и телбивудина (ldt)
MX2023001538A (es) Composiciones y metodos para inhibir la expresion de lpa.
MX2022008738A (es) Acidos nucleicos de fosfonato de 4'-o-metileno y analogos de estos.
MX2022005024A (es) Profarmacos de fosforo de estimuladores de guanilato ciclasa soluble (sgc).
NZ759764A (en) Glucuronide prodrugs of janus kinase inhibitors
ZA202109175B (en) Novel peptide compound or pharmaceutically acceptable salt thereof
CR20230130A (es) Proceso e intermedios para preparar un inhibidor de jak1
WO2015158317A8 (en) Use of a l,3j5-triazin-2-yl phosphoramidate compound in the synthesis of sofosbuvir
NZ746906A (en) Oxaborole esters and uses thereof
MX2022007628A (es) Combinaciones.
PH12020500198A1 (en) Therapeutic agent for fibrosis
MX2021009752A (es) Derivado de 7h-pirrolo[2,3-d]pirimidin-4-amina.
MX2021007511A (es) Procedimiento para la preparacion de anilinas sustituidas.
MX2022003879A (es) Proceso para elaborar acidos alcansulfonicos.